You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Molecular subtypes

Showing 1 - 25 of 5,891
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locoregional Recurrence of Breast Cancer

Not yet recruiting
  • Locoregional Recurrence
    • (no location specified)
    Aug 4, 2023

    Corresponding to Different Molecular Subtypes of Brest Cancer. A

    Completed
    • Breast Cancer
      • (no location specified)
      Feb 24, 2023

      Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

      Recruiting
      • Peripheral T Cell Lymphoma
      • Azacitidine Injection
      • +6 more
      • Shanghai, Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      Nov 8, 2022

      Shear-wave Elastography in Breast Cancer

      Not yet recruiting
      • Breast Cancer
      • elastography
      • (no location specified)
      Nov 3, 2023

      Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • 84-gene penal
      • Shandong, China
      • +2 more
      Jul 6, 2023

      PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in

      Recruiting
      • Breast Cancer Female
      • lifestyle
      • Santiago, Independencia, Chile
      • +7 more
      Aug 30, 2021

      MRI With PET / CT in Evaluation of Response to Neoadjuvant

      Completed
      • Breast Cancer
      • Chemotherapy Effect
      • Istanbul, Kadikoy, Turkey
        Istanbul Medeniyet University Goztepe City Hospital
      May 8, 2021

      Genetic Change Trial in Zhengzhou (Gene evolution and molecular response under Bevacizumab treatment)

      Recruiting
      • Genetic Change
      • Gene evolution and molecular response under Bevacizumab treatment
      • Zhengzhou, Henan, China
        Henan Provincial People's Hospital
      Aug 21, 2022

      Early-stage Breast Cancer, HER2-positive Breast Cancer Trial in Sweden (Docetaxel, Carboplatin, Trastuzumab)

      Terminated
      • Early-stage Breast Cancer
      • HER2-positive Breast Cancer
      • Göteborg, Sweden
      • +7 more
      Sep 22, 2021

      Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor Trial in Stockholm (Paclitaxel, Tamoxifen + Palbociclib,

      Active, not recruiting
      • Early-Stage Breast Carcinoma
      • Estrogen Receptor Positive Tumor
      • Stockholm, Sweden
      • +2 more
      Jul 30, 2021

      Bladder Cancer Trial in Durham (Tremelimumab, Durvalumab, Bladder radiation)

      Withdrawn
      • Bladder Cancer
      • Durham, North Carolina
        Duke University Medical Center
      Jul 1, 2020

      Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor Trial in Stockholm (Tamoxifen or Aromatase Inhibitor or Aromatase

      Active, not recruiting
      • Early-Stage Breast Carcinoma
      • Hormone Receptor Positive Tumor
      • Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin
      • Palbociclib
      • Stockholm, Sweden
        Department of Oncology, Karolinska University Hospital
      Jul 5, 2020

      Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

      Recruiting
      • SCLC,Extensive Stage
      • PD-(L)1 antibody immunotherapy
      • Beijing, Beijing, China
        Peking University Cancer Hospital & Institute
      Jul 3, 2023

      Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer Trial in Sweden (docetaxel + trastuzumab sc + pertuzumab, trastuzumab

      Active, not recruiting
      • Early-Stage Breast Carcinoma
      • HER-2 Positive Breast Cancer
      • docetaxel + trastuzumab sc + pertuzumab
      • trastuzumab emtansin
      • Örebro, Närke, Sweden
      • +6 more
      Aug 11, 2020

      Breast Tissue Study of Breast Diseases Among Women in Hong Kong

      Completed
      • Breast Cancer
        • Hong Kong, China
        • +1 more
        Mar 12, 2020

        Neuroendocrine Carcinoma, Grade 3 Trial in Seoul (Avelumab)

        Completed
        • Neuroendocrine Carcinoma, Grade 3
        • Seoul, Korea, Republic of
          Samsung Medical Center
        Dec 26, 2019

        Non-muscle-invasive Bladder Cancer Trial in Shanghai (BCG combined with Tislelizumab)

        Not yet recruiting
        • Non-muscle-invasive Bladder Cancer
        • BCG combined with Tislelizumab
        • Shanghai, Shanghai, China
          Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        Oct 12, 2022

        Breast Cancer With or Without BRCA Mutation

        Recruiting
        • Breast Cancer
        • Androgen receptor status and BRCA mutation
        • Varanasi, UP, India
          Banaras Hindu University
        Jun 2, 2022

        DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

        Not yet recruiting
        • DLBCL - Diffuse Large B Cell Lymphoma
        • Lymphoma
        • Other
        • Shanghai, Shanghai, China
          Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
        Sep 6, 2023

        Gastric Tumor, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Dresden, Heidelberg (Biopsy)

        Active, not recruiting
        • Gastric Neoplasm
        • +4 more
        • Biopsy
        • Dresden, Germany
        • +1 more
        Feb 22, 2022

        Determinants of Chronic Inflammatory Skin Disease Trajectories

        Recruiting
        • Atopic Dermatitis
        • +4 more
        • Topical and systemic drugs
        • Kiel, Germany
          Department of Dermatology and Allergy, University Hospital Schle
        Jun 22, 2023

        Gastric Cancer, Signet Ring Cell Carcinoma Trial in Hangzhou (Without any intervention)

        Active, not recruiting
        • Gastric Cancer
        • Signet Ring Cell Carcinoma
        • Without any intervention
        • Hangzhou, Zhejiang, China
          Cancer Hospital of the University of Chinese Academy of Sciences
        Aug 2, 2023

        Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

        Not yet recruiting
        • Triple-negative Breast Cancer
        • A1: SHR-A1811
        • +11 more
        • Shanghai, China
          Fudan University Shanghai Cancer Center
        Feb 19, 2023

        Breast Cancer Trial in Taipei City (PET/MR)

        Recruiting
        • Breast Cancer
        • PET/MR
        • Taipei City, Taiwan
          Department of Radiology,Taipei Veterans General Hospital
        Jul 18, 2022

        VIPER: Veterans Integrated Pain Evaluation Research

        Completed
        • Pain
          • Bethesda, Maryland
            Walter Reed National Military Medical Center
          Aug 13, 2019